Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy; safety and tolerability of ASP8062 compared with placebo ASP8062 as add-on therapy to buprenorphine/naloxone.


Clinical Trial Description

The study will consist of the following periods: Screening Period (up to 56 days); Double-blind treatment period (12 weeks/ 85 days); a Buprenorphine/naloxone down-titration period (as determined by the participant in collaboration with the investigator) (14 days); and a Follow-up period (30 days post last dose ASP8062 or placebo ASP8062 for ASP8062 End of Treatment [EOT]). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05062577
Study type Interventional
Source Astellas Pharma Inc
Contact Astellas Pharma Global Development, Inc.
Phone 800-888-7704
Email [email protected]
Status Not yet recruiting
Phase Phase 2
Start date September 30, 2021
Completion date February 28, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT05037682 - Pain and Opioid Management in Older Adults N/A
Not yet recruiting NCT04920864 - rTMS, Stress and Opioid Use Disorder N/A
Not yet recruiting NCT04231708 - Effects of Pharmacological Stress and rTMS on Executive Function in Opioid Use Disorder Phase 2
Completed NCT02559973 - Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder Phase 1
Completed NCT02593474 - Medication-Assisted Treatment for Youth With Substance Use Disorders Phase 1
Completed NCT02440256 - Expanded HIV Care in Opioid Substitution Treatment (EHOST) Trial N/A
Suspended NCT04577144 - An Observational Study of Environmental and Socioeconomic Factors in Opioid Recovery-Long Term
Not yet recruiting NCT04946656 - A Study of SPG Block for Opioid Withdrawal N/A
Completed NCT03033732 - A Pragmatic Randomized Control Trial Comparing Models of Care in the Management of Prescription Opioid Misuse Phase 4
Recruiting NCT03821337 - Transcranial Magnetic Stimulation (rTMS) as a Tool to Decrease Pain and Improve Functioning N/A
Not yet recruiting NCT05027919 - Assessing a Clinically-meaningful Opioid Withdrawal Phenotype Phase 2
Not yet recruiting NCT05051644 - An Adaptive Walking Intervention to Manage Chronic Pain in Veterans With Opioid Use Disorder Engaged in Opioid Agonist Treatment Phase 1
Recruiting NCT04375033 - A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder Phase 4
Completed NCT02942199 - MySafeRx & MedicaSafe Open-Label Buprenorphine Induction and Lapse Evaluation (MyMOBILE) N/A
Completed NCT02672111 - Long-Term Safety Study of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder Phase 3
Completed NCT02044094 - Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid Disorder Phase 2
Completed NCT02765867 - Single-dose, Study of RBP-6000 in Opioid Dependent Individuals Phase 1
Recruiting NCT04567784 - Neuroimaging and CBD for Heroin Use Disorder Phase 2
Recruiting NCT04238754 - Oral Cannabidiol for Opioid Withdrawal Phase 1/Phase 2
Completed NCT03944850 - Computerized Anxiety Sensitivity Treatment for Opioid Use Disorders N/A